LANSOPRAZOLE

PeakSM

lansoprazole

NDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Proton Pump Inhibitors

Pharmacologic Class:

Proton Pump Inhibitor

Clinical Trials (5)

NCT07313774Phase 3Not Yet Recruiting

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Started Mar 2026
1,050 enrolled
GERD (Gastroesophageal Reflux Disease)
NCT07037875Phase 3Not Yet Recruiting

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Started Sep 2025
500 enrolled
GERD (Gastroesophageal Reflux Disease)
NCT02442752Phase 1Withdrawn

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

Started Jun 2025
0
Pediatric Gastroesophageal Reflux Disease
NCT02615184Phase 2Recruiting

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Started May 2023
76 enrolled
Erosive Esophagitis
NCT02616302Phase 2Recruiting

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Started Feb 2023
70 enrolled
Gastroesophageal Reflux Disease (GERD)

Loss of Exclusivity

LOE Date
Apr 21, 2036
123 months away
Patent Expiry
Apr 21, 2036

Patent Records (2)

Patent #ExpiryTypeUse Code
11077055
Apr 21, 2036
Product
11986554
Apr 21, 2036
Product